False000166118100016611812024-02-292024-02-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):February 29, 2024

ORGANOGENESIS HOLDINGS INC.

(Exact Name of Registrant as specified in its charter)

Delaware	001-37906	98-1329150
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
85 Dan Road Canton, MA		02021
(Address of principal executive offices)		(Zip Code)

(781) 575-0775

(Registrant’s telephone number, including area code)

Not Applicable

(Registrant’s name or former address, if change since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Common Stock, $0.0001 par value		ORGO		Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. ☐

 

---

Item 2.02 Results of Operations and Financial Condition.

On February 29, 2024, the Company announced via press release its results for the fiscal fourth quarter and year ended December 31, 2023. A copy of the Company’s press release is hereby furnished to the Commission and incorporated herein by reference as Exhibit 99.1.

The information in the press release attached as Exhibit 99.1 is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release dated February 29, 2024
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Organogenesis Holdings Inc.
By:	/s/ Lori Freedman
Name:	Lori Freedman
Title:	Chief Administrative and Legal Officer

 

Date: February 29, 2024

 

---

 

 

FOR IMMEDIATE RELEASE

 

Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance

 

CANTON, Mass., (February 29, 2024) – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2023.

 

Fourth Quarter 2023 Financial Results Summary:

 

 

Fiscal Year 2023 Financial Results Summary:

 

 

“We are building positive momentum with the many commercial support programs implemented to enhance existing customer relationships and regain lost accounts in a uniquely challenging operating environment”, said

---

Gary S. Gillheeney, Sr., President and Chief Executive Officer of Organogenesis. "Despite the expected operating environment challenges, we delivered revenues within the lower end of our guidance. Looking ahead to 2024, we expect to return to revenue growth through continued demonstration of value to our customers and new product launches in both our Advanced Wound Care and Surgical & Sports Medicine markets broadening our portfolio of differentiated treatment options.”

Mr. Gillheeney, Sr. continued: “We continue to make progress with the ReNu program, which we believe, represents a significant value driver by addressing a critical unmet need in treating the symptoms of knee osteoarthritis. We remain confident in the long-term opportunity for Organogenesis and expect to continue to lead in our space with highly innovative products that deliver on our mission to provide integrated healing solutions that substantially improve outcomes while lowering the overall cost of care.”

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1Defined as GAAP net income adjusted to exclude the effect of amortization, restructuring charges, LCD legal fees and sales retention, write-off of certain assets, facility construction project pause, GPO settlement fee and the resulting income taxes on these items.

 

 

---

Fourth Quarter 2023 Financial Results:


 

		Three Month Ended December 31,								Change
		2023				2022				$				%
		(in thousands, except for percentages)
Advanced Wound Care		$	93,165			$	108,836			$	(15,671	)			(14	%)
Surgical & Sports Medicine			6,486				6,680				(194	)			(3	%)
Net revenue		$	99,651			$	115,516			$	(15,865	)			(14	%)

 

Net revenue for the fourth quarter of 2023 was $99.7 million, compared to $115.5 million for the fourth quarter of 2022, a decrease of $15.9 million, or 14%. The decrease in net revenue was driven by a decrease of $15.7 million, or 14% in net revenue of Advanced Wound Care products and a decrease of $0.2 million, or 3% in net revenue of Surgical & Sports Medicine products.

 

Gross profit for the fourth quarter of 2023 was $71.9 million, or 72% of net revenue, compared to $88.4 million or 77% of net revenue, for the fourth quarter of 2022, a decrease of $16.5 million, or 19%.

 

Operating expenses for the fourth quarter of 2023 were $73.2 million, compared to $79.7 million for the fourth quarter of 2022, a decrease of $6.5 million, or 8%. R&D expenses were $11.8 million for the fourth quarter of 2023, compared to $11.4 million in the fourth quarter of 2022, an increase of $0.4 million, or 3%. Selling, general and administrative expenses were $61.4 million, compared to $68.3 million in the fourth quarter of 2022, a decrease of $6.9 million, or 10%.

 

Operating loss for the fourth quarter of 2023 was $1.3 million, compared to operating income of $8.7 million for the fourth quarter of 2022, a decrease of $10.0 million.

 

Total other expense, net, for the fourth quarter of 2023 was $0.5 million, compared to other income, net of less than $0.1 million for the fourth quarter of 2022, a decrease of approximately $0.6 million.

 

Net loss for the fourth quarter of 2023 was $0.6 million, or $(0.00) per share, compared to net income of $7.5 million, or $0.06 per share, for the fourth quarter of 2022, a decrease of $8.1 million, or $0.06 per share.

Adjusted net income was $1.9 million for the fourth quarter of 2023, compared to adjusted net income of $8.9 million for the fourth quarter of 2022, a decrease of $7.0 million, or 78%.

 

Adjusted EBITDA was $7.5 million for the fourth quarter of 2023, compared to $14.1 million for the fourth quarter of 2022, a decrease of $6.6 million, or 47%.

 

As of December 31, 2023, the Company had $104.3 million in cash, cash equivalents and restricted cash and $66.2 million in term loan debt obligations, compared to $103.3 million in cash, cash equivalents and restricted cash and $70.8 million in term loan debt obligations, as of December 31, 2022.

 

 

---

Fiscal Year 2023 Results

The following table represents net revenue by product grouping for the year ended December 31, 2023 and December 31, 2022, respectively:

		Year Ended December 31,								Change
		2023				2022				$				%
		(in thousands, except for percentages)
Advanced Wound Care		$	405,514			$	422,231			$	(16,717	)			(4	%)
Surgical & Sports Medicine			27,626				28,662				(1,036	)			(4	%)
Net revenue		$	433,140			$	450,893			$	(17,753	)			(4	%)

 

Net revenue for the year ended December 31, 2023 was $433.1 million, compared to $450.9 million for the year ended December 31, 2022, a decrease of $17.8 million, or 4%. The decrease in net revenue was driven by a decrease of $16.7 million, or 4% in net revenue of Advanced Wound Care products and a decrease of $1.0 million, or 4% in net revenue of Surgical & Sports Medicine products.

 

Gross profit for the year ended December 31, 2023 is $326.7 million, or 75% of net revenue, compared to $345.9 million, or 77% of net revenue, for the year ended December 31, 2022, a decrease of $19.2 million, or 6%.

 

Operating expenses for the year ended December 31, 2023 were $314.1 million, compared to $323.6 million for the year ended December 31, 2022, a decrease of $9.4 million, or 3%. R&D expenses were $44.4 million for the year ended December 31, 2023, compared to $39.8 million for year ended December 31, 2022, an increase of $4.6 million, or 12%. Selling, general and administrative expenses were $269.8 million for year ended December 31, 2023, compared to $283.8 million year ended December 31, 2022, a decrease of $14.1 million, or 5%.

 

Operating income for the year ended December 31, 2023 was $12.5 million, compared to an operating income of $22.3 million for the year ended December 31, 2022, a decrease of $9.8 million.

 

Total other expense, net, for the year ended December 31, 2023 was $2.1 million, compared to $2.0 million for the year ended December 31, 2022, a decrease of $0.1 million.

 

Net income of $4.9 million for the year ended December 31, 2023 or $0.04 per share, compared to net income of $15.5 million, or $0.12 per share for the year ended December 31, 2022, a decrease of $10.5 million, or $0.08 per share.

 

Adjusted net income for the year ended December 31, 2023 was $12.7 million., compared to $26.2 million for the year ended December 31, 2022, a decrease of $13.5 million, or 52%.

 

Adjusted EBITDA of $42.6 million for the year ended December 31, 2023, compared to Adjusted EBITDA of $49.3 million for the year ended December 31, 2022, a decrease of $6.7 million, or 14%.

 

---

Fiscal Year 2024 Guidance:

 

For the year ending December 31, 2024, the Company expects:

 

 

 

Earnings Conference Call:

 

Financial results for the fourth fiscal quarter and year ended December 31, 2023 will be reported after the market closes on Thursday, February 29th. Management will host a conference call at 5:00 p.m. Eastern Time on February 29th to discuss the results of the quarter, and provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. A live webcast of the call will also be provided on the investor relations section of the Company's website at investors.organogenesis.com.

For those unable to participate, the webcast will be archived at investors.organogenesis.com for approximately one year.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

---

ORGANOGENESIS HOLDINGS INC.

UNAUDITED CONSOLIDATED BALANCE SHEETS

(amounts in thousands, except share and per share data)

 

		December 31,
		2023				2022
Assets
Current assets:
Cash and cash equivalents		$	103,840			$	102,478
Restricted cash			498				812
Accounts receivable, net			81,999				89,450
Inventories			28,253				24,783
Prepaid expenses and other current assets			10,454				5,086
Total current assets			225,044				222,609
Property and equipment, net			116,228				102,463
Intangible assets, net			15,871				20,789
Goodwill			28,772				28,772
Operating lease right-of-use assets, net			40,118				43,192
Deferred tax asset, net			28,002				30,014
Other assets			5,990				1,520
Total assets		$	460,025			$	449,359
Liabilities and Stockholders’ Equity
Current liabilities:
Current portion of term loan		$	5,486			$	4,538
Current portion of finance lease obligations			1,081				—
Current portion of operating lease obligations - related party			3,140				3,001
Current portion of operating lease obligations			10,004				8,707
Accounts payable			30,724				32,330
Accrued expenses and other current liabilities			30,074				26,447
Total current liabilities			80,509				75,023
Term loan, net of current portion			60,745				66,231
Finance lease obligations, net of current portion			1,888				—
Operating lease obligations, net of current portion - related party			17,227				20,367
Operating lease obligations, net of current portion			19,780				20,947
Other liabilities			1,213				1,122
Total liabilities			181,362				183,690
Commitments and contingencies (Note 18)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued			—				—
Common stock, $0.0001 par value; 400,000,000 shares authorized; 132,044,944 and 131,647,677 shares issued; 131,316,396 and 130,919,129 shares outstanding at December 31, 2023 and 2022, respectively.			13				13
Additional paid-in capital			319,621				310,957
Accumulated deficit			(40,971	)			(45,301	)
Total stockholders' equity			278,663				265,669
Total liabilities and stockholders' equity		$	460,025			$	449,359

 

---

ORGANOGENESIS HOLDINGS INC. UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

(amounts in thousands, except share and per share data)

 

		Three Months Ended December 31,								Year Ended December 31,
		2023				2022				2023				2022
Net revenue		$	99,651			$	115,516			$	433,140			$	450,893
Cost of goods sold			27,769				27,110				106,481				105,019
Gross profit			71,882				88,406				326,659				345,874
Operating expenses:
Selling, general and administrative			61,381				68,293				269,754				283,808
Research and development			11,770				11,395				44,380				39,762
Total operating expenses			73,151				79,688				314,134				323,570
Loss (income) from operations			(1,269	)			8,718				12,525				22,304
Other expense, net:
Interest expense, net			(502	)			30				(2,190	)			(2,009	)
Other income (expense), net			(25	)			6				57				(13	)
Total other expense, net			(527	)			36				(2,133	)			(2,022	)
Net income before income taxes			(1,796	)			8,754				10,392				20,282
Income tax (expense) benefit			1,228				(1,268	)			(5,447	)			(4,750	)
Net (loss) income and comprehensive (loss) income		$	(568	)		$	7,486			$	4,945			$	15,532
Net income, per share:
Basic		$	(0.00	)		$	0.06			$	0.04			$	0.12
Diluted		$	(0.00	)		$	0.06			$	0.04			$	0.12
Weighted-average common shares outstanding
Basic			130,916,950				128,661,435				131,231,317				130,070,231
Diluted			131,857,509				133,348,995				132,746,727				132,383,152

 

 

---

ORGANOGENESIS HOLDINGS INC. UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS

(amounts in thousands, except share and per share data)

 

		Year Ended December 31,
		2023				2022				2021
Cash flows from operating activities:
Net income		$	4,945			$	15,532			$	94,202
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation			10,448				5,845				5,781
Amortization of intangible assets			4,918				4,883				4,949
Amortization of operating lease right-of-use assets			8,083				7,303				5,946
Non-cash interest expense			427				434				346
Deferred interest expense			490				501				1,493
Deferred tax expense (benefit)			2,012				1,980				(31,976	)
Loss on disposal of property and equipment			235				4,482				1,407
Loss on lease termination			559				—				—
Provision recorded for credit losses			1,297				1,781				2,999
Adjustment for excess and obsolete inventories			6,580				9,648				12,079
Stock-based compensation			8,996				6,552				3,864
Loss on extinguishment of debt			—				—				1,883
Change in fair value of earnout liability			—				—				(3,985	)
Changes in operating assets and liabilities:
Accounts receivable			5,539				(8,770	)			(28,654	)
Inventories			(8,179	)			(9,410	)			(9,302	)
Prepaid expenses and other current and other assets			(10,115	)			(378	)			(34	)
Operating leases			(8,439	)			(7,006	)			(6,156	)
Accounts payable			(108	)			3,260				3,847
Accrued expenses and other current liabilities			3,138				(11,850	)			9,354
Other liabilities			91				72				(6,065	)
Net cash provided by operating activities			30,917				24,859				61,978
Cash flows from investing activities:
Purchases of property and equipment			(24,364	)			(33,898	)			(31,220	)
Net cash used in investing activities			(24,364	)			(33,898	)			(31,220	)
Cash flows from financing activities:
Line of credit repayments under the 2019 Credit Agreement			—				—				(10,000	)
Term loan repayments under the 2019 Credit Agreement			—				—				(60,000	)
Proceeds from term loan under the 2021 Credit Agreement, net of debt discount and issuance cost			—				—				73,174
Term loan repayments under the 2021 Credit Agreement			(4,688	)			(2,813	)			(938	)
Principal repayments of finance lease obligations			(485	)			(200	)			(2,630	)
Proceeds from the exercise of stock options			—				2,070				2,198
Payments of withholding taxes in connection with RSUs vesting			(332	)			(648	)			(737	)
Payments of deferred acquisition consideration			—				(608	)			(483	)
Payment to extinguish debt			—				—				(1,620	)
Net cash used in financing activities			(5,505	)			(2,199	)			(1,036	)
Change in cash, cash equivalents and restricted cash			1,048				(11,238	)			29,722
Cash, cash equivalents, and restricted cash, beginning of year			103,290				114,528				84,806
Cash, cash equivalents, and restricted cash, end of year		$	104,338			$	103,290			$	114,528
Supplemental disclosure of cash flow information:
Cash paid for interest		$	5,436			$	2,649			$	5,787
Cash paid for income taxes		$	3,052			$	1,201			$	607
Supplemental disclosure of non-cash investing and financing activities:
Cumulative effect adjustment for adoption of ASU No. 2016-13 (Note 2)		$	615			$	—			$	—
Deferred acquisition consideration and earnout liability recorded for business acquisition		$	—			$	828			$	—
Purchases of property and equipment in accounts payable and accrued expenses		$	841			$	1,928			$	3,750
Right-of-use assets obtained through operating lease obligations		$	5,869			$	1,350			$	53,793
Right-of-use assets obtained through finance lease obligations		$	3,454			$	—			$	—

 

 

 

 

---

Non-GAAP Financial Measures

Our management uses financial measures that are not in accordance with generally accepted accounting principles in the United States, or GAAP, in addition to financial measures in accordance with GAAP to evaluate our operating results. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with GAAP. Our management uses Adjusted EBITDA and adjusted net income to evaluate our operating performance and trends and make planning decisions. Our management believes Adjusted EBITDA and adjusted net income help identify underlying trends in our business that could otherwise be masked by the effect of the items that we exclude. Accordingly, we believe that Adjusted EBITDA and adjusted net income provide useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and prospects, and allowing for greater transparency with respect to key financial metrics used by our management in its financial and operational decision-making.

The following table presents a reconciliation of GAAP net income to non-GAAP EBITDA and non-GAAP Adjusted EBITDA, for each of the periods presented:

		Three Months Ended December 31,								Year Ended December 31,
($, in thousands)		2023				2022				2023				2022
Net (loss) income		$	(568	)		$	7,486			$	4,945			$	15,532
Interest expense, net			502				(30	)			2,190				2,009
Income tax expense (benefit)			(1,228	)			1,268				5,447				4,750
Depreciation			2,982				1,514				10,448				5,845
Amortization			1,229				1,221				4,918				4,883
EBITDA			2,917				11,459				27,948				33,019
Stock-based compensation expense			2,366				1,855				8,996				6,552
Restructuring charge (1)			1,918				750				3,796				2,268
Write-off of certain assets (2)			—				—				—				4,200
Settlement fee (3)			—				—				—				2,600
Facility construction project pause (4)			—				—				—				632
Legal fees (5)			—				—				1,182				—
Sales retention (6)			272				—				694				—
Adjusted EBITDA		$	7,473			$	14,064			$	42,616			$	49,271

 

---

The following table presents a reconciliation of GAAP net income to non-GAAP adjusted net income, for each of the periods presented:

		Three Months Ended December 31,								Year Ended December 31,
($, in thousands)		2023				2022				2023				2022
Net (loss) income		$	(568	)		$	7,486			$	4,945			$	15,532
Amortization			1,229				1,221				4,918				4,883
Restructuring charge (1)			1,918				750				3,796				2,268
Write-off of certain assets (2)			—				—				—				4,200
Settlement fee (3)			—				—				—				2,600
Facility construction project pause (4)			—				—				—				632
Legal fees (5)			—				—				1,182				—
Sales retention (6)			272				—				694				—
Tax on above			(923	)			(527	)			(2,859	)			(3,898	)
Adjusted net income		$	1,928			$	8,930			$	12,676			$	26,217

 

The following table presents a reconciliation of projected GAAP net income (loss) to projected non-GAAP EBITDA and projected non-GAAP Adjusted EBITDA included in our guidance for the year ending December 31, 2024:

 

		Year Ended December 31,
($, in thousands)		2024L				2024H
Net (loss) income		$	(10,565	)		$	4,616
Interest expense, net			3,000				2,200
Income tax expense (benefit)			308				5,061
Depreciation			9,680				9,680
Amortization			3,400				3,400
EBITDA			5,823				24,957
Stock-based compensation expense			10,000				10,000
Restructuring charge			-				-
Adjusted EBITDA			15,823				34,957

The following table presents a reconciliation of projected GAAP net income (loss) to projected non-GAAP adjusted net income included in our guidance for the year ending December 31, 2024:

 

		Year Ended December 31,
($, in thousands)		2024L				2024H
Net (loss) income		$	(10,565	)		$	4,616
Amortization			3,400				3,400
Restructuring charge			—				—
Tax on above			(918	)			(918	)
Adjusted net (loss) income		$	(8,083	)		$	7,098

 

---

Forward-Looking Statements

 

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include statements relating to the Company’s expected revenue, net income, adjusted net income, EBITDA, and Adjusted EBITDA for fiscal 2024 and the breakdown of expected revenue in both its Advanced Wound Care and Surgical & Sports Medicine categories. Forward-looking statements with respect to the operations of the Company, strategies, prospects, and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the reimbursement levels for the Company’s products; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company’s products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete; (4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company’s ability to raise funds to expand its business; (6) the Company has incurred losses in prior years and may incur losses in the future; (7) changes in applicable laws or regulations; (8) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (9) the Company’s ability to maintain production or obtain supply of its products in sufficient quantities to meet demand; (10) any resurgence of the COVID-19 pandemic and its impact, if any, on the Company’s fiscal condition and results of operations; (11) the impact of the suspension of commercialization of: (a) ReNu and NuCel in connection with the expiration of the FDA’s enforcement grace period for HCT/Ps on May 31, 2021 and (b) Dermagraft in the second quarter of 2022 pending transition of manufacturing to a new manufacturing facility or a third-party manufacturer; and (12) other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including Item 1A (Risk Factors) of the Company’s Form 10-K for the year ended December 31, 2023 and its subsequently filed periodic reports. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

 

 

 

 

 

 

 

---

About Organogenesis Holdings Inc.

Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit www.organogenesis.com.

 

Investor Inquiries:
Westwicke Partners
Mike Piccinino, CFA
OrganoIR@westwicke.com
443-213-0500

 

Press and Media Inquiries:
Organogenesis

Lori Freedman

LFreedman@organo.com

---